Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

I’m not going to report record revenue, but it was nonetheless a robust year," CEO Bernard Arnault said during the earnings ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, ...

Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...

Trump has also questioned whether Denmark, which has controlled Greenland since 1814, has a "legal right" to the territory and predicted that Greenland's people will vote to join the U.S. He ...

Market Structure ? Growth Drivers ? Restraints and Challenges ? Emerging Product Trends & Market Opportunities ? Porter?s Fiver Forces The trend and outlook of global market is forecast in optimistic, ...

Europe pharmaceutical manufacturing industry market was valued at $2.84 billion in 2022 and will grow by 8.6% annually over 2022-2032. The growth is driven by the increased drug approvals, increasing ...

$ 87.86-0.11-0.13% ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...